 |
A Note from Bill Andrews, President and CEO
If this is the first issue of our newsletter that you're receiving, you may want to read part one, first. Our older newsletters are archived on our website, at www.sierrasci.com/newsletters/. Part one can be found in the September 2009 issue. Remember: this newsletter is an opt-in publication. Since this is the third issue of the newsletter, if you have not opted in already, and you don't opt in now, this will be the last issue you receive. If you want to continue to receive this newsletter, be sure to click the "opt me in" link at the bottom. If you have already opted in, there's no need to do it a second time. I've received a lot of great feedback on our last newsletter. I'd like to thank those of you who asked questions and shared your ideas on the risk of cancer in telomerase activation, as well as those of you who attended or viewed my presentations at A4M San Jose, at TA Sciences in New York, or at the Roger Smith Hotel in New York. Thank you again for your continued interest in Sierra Sciences! William H. Andrews, Ph.D. William H. Andrews, Ph.D. Part 2 of 2 When our immune system gets weak it loses the ability to fight cancer cells. This is, for example, why AIDS patients that have lost their T cells due to telomere shortening have a significantly increased risk of getting cancer, such as Kaposi's Sarcoma. This is probably also an explanation of why cancer is so much more prevalent in the elderly who typically have age-related weakened immune systems. So, we are left with the "pre-immortal cancer cells" that have short telomeres. Inducing telomerase expression should extend the lifespan of these cells; and therein lays the grounds for controversy. And, no one knows how big a problem this is, if at all. For example, no one that I've ever talked to knows the prevalence of "pre-immortal cancer cells" in humans. There are many factors at play here:
No one knows the magnitude of each factor described above. Will the good factors outweigh the bad factors? Or, visa versa. No one knows. But, its not just telomerase induction that we need to be concerned about. No matter what we do to extend the lifespan of our cells, whether it be by telomerase induction or not, we will extend the lifespan of our cancer cells, because our cancer cells are our cells too. So, we might find that the only way to extend lifespan is to cure cancer. Given the lack of clarity of everything described above, people, such as myself, that have elected to take TA-65, and look forward to taking even stronger telomerase inducers in the future, must act totally on gut feelings. I personally feel that taking a telomerase inducer is safer than driving my car to work. And, if I had cancer, I would take as much telomerase inducer as I could get my hands on to help my body fight the cancer.
|
SIERRA SCIENCES NEWSBased on the tremendous response we got to Dr. Andrews' presentation on September 29 at the Roger Smith Hotel, he'll be visiting again next month, on Tuesday, November 17, 2009. If you couldn't make it to the last presentation, be sure not to miss this one! The Roger Smith hotel is less than five minutes from Grand Central Station, at 501 Lexington Avenue, NY 10017. If you plan to be in New York on this date, this is a talk you don't want to miss. The presentation will focus on telomere biology and the potential of telomerase activation to cure human aging. A question and answer session will be held afterwards. Seating is limited, but there are still slots available. If you're interested in attending the talk, please send an e-mail to jcornell@sierrasci.com. Last month, we told you about David Kekich's Manhattan Beach Project, a longevity summit bringing people passionate about curing aging together from all over the world to form a comprehensive plan for defeating aging. It will be held from November 13 to November 15 in Manhattan Beach, California. That summit is quickly approaching. Dr. Andrews is scheduled to speak on the morning of Friday, November 13. The Manhattan Beach Project is an invitation-only summit, but if you're a scientist interested in attending, please contact us, or Dr. Kekich. For more details, please see: http://maxlife.org/m_beach_project.asp Dr. Andrews will be giving a presentation entitled "Hormone Optimization and the Telomere Link" on November 7, 2009 at the Age Medical Management Group (AMMG) conference in Las Vegas, NV. The conference begins Thursday, November 5, and runs through Sunday, November 8. AMMG is a group that provides education and information on the new sub-specialty of Age Management Medicine to physicians and healthcare professionals through evidence based continuing medical education conferences, workshops, seminars, publications and web media. For more information, see their website, at: http://www.agemed.org. ANTI-AGING NEWS
It's been nearly three decades since these scientists characterized the telomere and discovered the telomerase enzyme in the ciliate Tetrahymena. Earlier this month, the Nobel Committee finally recognized the importance of these discoveries. The Nobel Committee has a solid track record of identifying the discoverers of scientific principles that become the basis for the most important medical technologies of our age. The Nobel Prize in Medicine has formerly gone to scientists who characterized hormones, antibodies, vaccines, blood types, and even insulin. We're confident that someday, telomeres and telomerase will be household words in this same vein - and therapies that take advantage of them will be just as common. Congratulations!
Sierra Sciences has a Facebook page that we use to keep our supporters up to date on the progress of our company. If you have a Facebook profile, you can receive these updates by "becoming a fan" of the company. Just visit this address and click "Become a Fan": Hope to see you there! http://www.facebook.com/home.php?#/pages/Sierra-Sciences/130839216671?ref=nf
|
|||||
|
||||||
I WOULD LIKE TO OPT-IN, PLEASE CONTINUE TO SEND ME EMAIL NEWSLETTERS
I would like to recommend this to a friend.
Sierra Sciences - 10/28/2009 - Volume 1, No. 3
As promised, here is the second and final part of my synopsis on the risk of cancer in telomerase activation.
What follows is that if we induce telomerase expression it should help our immune cells to stay strong enough to fight cancers and it should prevent telomeres from getting short enough to induce cancers. Since immortal cancer cells are already immortal inducing telomerase in these cells is not going to make them more immortal. The same can be said for pre-immortal cancer cells that have very long telomeres.
